Future Medicinal Chemistry

Systematic prioritization of cancer combination therapies: are we really on target?
pp. 387-389(3)
Author: Lee, Margaret S

News & Analysis
pp. 391-394(4)

The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules
pp. 395-424(30)
Authors: Węsierska-Gądek, Józefa; Kramer, Matthias P

Current limitations and future opportunities for epigenetic therapies
pp. 425-446(22)
Authors: Cherblanc, F; Chapman-Rothe, N; Brown, R; Fuchter, MJ

EGFR/HER-targeted therapeutics in ovarian cancer
pp. 447-469(23)
Authors: Wilken, Jason A; Badri, Tayf; Cross, Sarah; Raji, Rhoda; Santin, Alessandro D; Schwartz, Peter; Branscum, Adam J; Baron, Andre T; Sakhitab, Adam I; Maihle, Nita J

HDAC inhibitors for the treatment of cutaneous T-cell lymphomas
pp. 471-486(16)
Authors: Rangwala, Sophia; Zhang, Chunlei; Duvic, Madeleine

mTOR kinase inhibitors as a treatment strategy in hematological malignancies
pp. 487-504(18)
Authors: Grzybowska-Izydorczyk, Olga; Smolewski, Piotr

Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
pp. 505-524(20)
Authors: Gryder, Berkley E; Sodji, Quaovi H; Oyelere, Adegboyega K

Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future
pp. 525-543(19)
Authors: Dalla Via, Lisa; Nardon, Chiara; Fregona, Dolores

Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies
pp. 545-584(40)
Authors: Hevey, Rachel; Ling, Chang-Chun

Acknowledgements
pp. 585-585(1)